MedPath

A randomized multicenter study of carboplatin-gemcitabine versus carboplatin-paclitaxel in elderly patients with non-small cell lung cancer with emphasis on geriatric assessment and quality of life: The NVALT-3 study.

Completed
Conditions
on Small Lungcancer (NSCLC) (NLD: Niet Kleincellig Longcarcinoom).
Registration Number
NL-OMON26629
Lead Sponsor
VALT
Brief Summary

/A

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
182
Inclusion Criteria

1. Histologically or cytologically confirmed inoperable (stage III) or disseminated (stage IV) non small cell lung cancer;

2. No previous chemo- and or radiotherapy;

Exclusion Criteria

1. Patients with a mixed form of NSCLC and SCLC;

2. Active uncontrolled infection;

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To compare changes in quality of life between the two treatment groups from baseline as compared with quality of life at 18 weeks after start treatment.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath